Glaukos Corporation (GKOS) Upgraded at Zacks Investment Research
Zacks Investment Research upgraded shares of Glaukos Corporation (NYSE:GKOS) from a hold rating to a buy rating in a report issued on Friday. They currently have $41.00 price target on the medical instruments supplier’s stock.
According to Zacks, “Glaukos Corporation is an ophthalmic medical technology company. The Company develops, manufactures and markets medical devices for the treatment of glaucoma. Its product pipeline consists of iStent Inject, the iStent Supra and iDose. The company operates primarily in United States, Germany, Europe, the Asia Pacific, Canada and internationally. Glaukos Corporation is headquartered in Laguna Hills, California. “
GKOS has been the topic of several other reports. Roth Capital lowered their target price on Glaukos Corporation from $60.00 to $54.00 and set a buy rating on the stock in a research note on Thursday. BidaskClub upgraded Glaukos Corporation from a hold rating to a buy rating in a research note on Saturday, June 24th. TheStreet downgraded Glaukos Corporation from a c rating to a d+ rating in a research note on Wednesday, May 3rd. Cantor Fitzgerald reiterated an overweight rating and issued a $54.00 target price on shares of Glaukos Corporation in a research note on Thursday, May 4th. Finally, BMO Capital Markets reiterated a buy rating and issued a $54.00 target price on shares of Glaukos Corporation in a research note on Tuesday, April 11th. One investment analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of $52.33.
Shares of Glaukos Corporation (GKOS) traded down 0.11% on Friday, reaching $36.22. The company’s stock had a trading volume of 90,556 shares. The company’s market capitalization is $1.25 billion. The stock has a 50-day moving average price of $41.36 and a 200-day moving average price of $43.37. Glaukos Corporation has a 1-year low of $28.26 and a 1-year high of $52.49.
WARNING: This article was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.dailypolitical.com/2017/08/07/glaukos-corporation-gkos-upgraded-at-zacks-investment-research.html.
Several hedge funds have recently bought and sold shares of GKOS. Janus Capital Management LLC boosted its stake in Glaukos Corporation by 88.5% in the first quarter. Janus Capital Management LLC now owns 1,765,069 shares of the medical instruments supplier’s stock valued at $90,545,000 after buying an additional 828,567 shares in the last quarter. Wells Fargo & Company MN boosted its stake in Glaukos Corporation by 73.2% in the first quarter. Wells Fargo & Company MN now owns 1,156,562 shares of the medical instruments supplier’s stock valued at $59,332,000 after buying an additional 488,730 shares in the last quarter. Alliancebernstein L.P. boosted its stake in Glaukos Corporation by 43.6% in the first quarter. Alliancebernstein L.P. now owns 1,291,882 shares of the medical instruments supplier’s stock valued at $66,274,000 after buying an additional 392,476 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Glaukos Corporation by 42.1% in the first quarter. Renaissance Technologies LLC now owns 1,206,200 shares of the medical instruments supplier’s stock valued at $61,878,000 after buying an additional 357,200 shares in the last quarter. Finally, Peregrine Capital Management LLC acquired a new stake in Glaukos Corporation during the second quarter valued at approximately $13,645,000. 89.63% of the stock is owned by institutional investors and hedge funds.
About Glaukos Corporation
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.